Work

Supplementary Figure S5 from Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies

Year: 2023

Type: supplementary-materials

Abstract: Supplemental Figure 5. Tumor biopsy gene expression changes in chemokine, cytokine and TLR related signaling pathways after SYNB1891 treatment.

DOI: 10.1158/1078-0432.23183897

Authors: Jason J. Luke, Sarina A. Piha-Paul, Theresa Medina, Claire F. Verschraegen, Mary Varterasian, Aoife M. Brennan, Richard J. Riese, Anna Sokolovska, James Strauss, David L. Hava, Filip Janku

Language: English

Topic: Bacterial Cancer Therapy

Subfield: Biotechnology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4378215358

Cites:

Cited by:

Related to: